Deprescribing to optimise health outcomes for frail older people: a double-blind placebo-controlled randomised controlled trial—outcomes of the Opti-med study

Christopher Etherton‐Beer(The University of Western Australia), Dee Mangin(University of Otago), Amy Page(The University of Western Australia), Andrew J. McLachlan(The University of Sydney), Tracy Comans(Queensland University of Technology), Richard I. Lindley(Westmead Hospital), Sarah N. Hilmer(Northern Sydney Local Health District), Kathleen N. Potter(University of Southampton), Vasi Naganathan(The University of Sydney)
Age and Ageing
May 1, 2023
10.1093/ageing/afad081
Cited by 28

Related Papers

Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
|The Lancet|2014|2.7k
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
|The Lancet|2012|1.2k
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
|Journal of Clinical Epidemiology|2012|1.2k
Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
|The Lancet|2012|1k